Zymeworks Inc.

Good day and thank you for standing by. Welcome to ZymeWorks first quarter 2026 results conference call. At this time, all participants are in the listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during your session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, Please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Chanel Inmadar, VP of Investor Relations. Your line is open.

Thank you, Operator. Good afternoon, everyone, and thank you for joining our first quarter 2026 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including without limitation those forward-looking statements identified on our slides and the accompanying oral commentary. These forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties including those associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we'll refer you to our latest SUT filings as found on our website and as followed by the SUT. In a moment, I'll hand over the call to Ken Galbraith, our Chair and CEO, who will provide an overview of recent business updates. Ken will then hand the call over to Kristen Stafford, our Chief Financial Officer, to discuss our cash position and financial results for the first quarter of 2026. Dr. Paul Moore will then provide a brief summary of new preclinical data disclosed at AACR on our PAN RAS ABCs. And following this, Dr. Sabine Mikan, our SVP and Chief Medical Officer, will provide progress updates on both the Phase 1 clinical trial of CW191 and CW251. At the end of the call, Ken, Kristen, Sabine, and Paul will be joined for a Q&A session with Scott Pashton, our Chief Business Officer, and Adam Shaywitz, Head of R&D. As a reminder, the audio and slides from this call will also be available on the Climber website later today. I'll now hand the call over to Ken.

Thank you, Chanel, and good afternoon, everyone. We're pleased to be reporting on further progress this quarter on both our wholly owned and partnered assets. The PDUFA date of August 25th, 2026 for Xanadatamab and first-line GEA in the U.S., together with the completion of an SPLA filing in China for first-line GEA, marks an important inflection point in near-term foundational value-driving opportunity for Zymorx. These regulatory milestones provide increasing visibility toward commercialization in first-line HER2-positive GEA and accompany continued clinical development in additional settings, such as breast cancer, helping to establish a clear baseline for Xanadatamab's value. If you didn't get a chance to tune in, we'd urge you to listen into Jazz's disclosures within their earnings call earlier this week on preparedness and launch activities for GEA in anticipation of an FDA approval later this year on or before the PDUFA date. With our partners Jazz and B1 bringing established commercial capabilities, we believe Santa Data Map is well positioned to translate potential approvals and label extensions into meaningful uptake significant milestone payments, and durable royalty revenues. This includes near-term milestone payments of $250 million upon approval in the U.S. for GEA from Jazz and $15 million upon approval in China for GA from B1. Importantly, this momentum also illustrates the broader strength of our business model. Recent data presented at the American Association for Cancer Research annual meeting, alongside this continued regulatory progress for Zandatamab, reinforce the strategic advantage of integrating our R&D portfolio with royalty participation within a single organization. We will continue to be intentional about maintaining a portion of our R&D portfolio unencumbered, preserving optionality for future transactions, and aiming to capture upside beyond structured royalty streams. Advances across our ADC portfolio at ADCR, including the presentation of three new preclinical RAS-targeting ADC candidates featuring proprietary payloads, as well as encouraging phase one data for ZW191, highlight the scalability of our platform and its ability to generate multiple potential future value drivers. Taken together, we believe this integrated model, anchored by near-term catalysts, such as potential global approvals for Zeta DataMap, and supported by a productive and innovative pipeline that provides future optionality for our emerging royalty portfolio, positions us to deliver durable compounding returns for shareholders over time. Over the past quarter, we've also strengthened our leadership team with the addition of Kristen and the full-time appointments of Scott and Adam, who bring deep experience in strategic capital allocation, investment, and dealmaking. Also pleased to announce the appointment today of Mr. Paul Schneider, who joins us as General Counsel from Pfizer. All of these appointments enhance our ability to systematically identify, structure, and execute opportunities that align with our long-term value creation framework. With that, I'd like to hand the call over to Kristen, who will provide an overview of our financial highlights for the first quarter of 2026.